⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Vicero Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Vicero Bio
↗Cambridge, USA
Vicero Bio is a preclinical-stage biopharmaceutical company focused on revolutionizing cancer immunotherapy through its proprietary VINCOBODY® platform. The company develops modular, multivalent VHH (single-domain antibody) therapeutics designed to overcome the limitations of conventional immunotherapies, such as toxicity and poor tumor penetration, by enabling multi-target combinations and multi-payload antibody-drug conjugates (ADCs).
Headquartered in Cambridge, Massachusetts, the company is building a pipeline of next-generation immuno-oncology assets. Its lead program, VCR-036, is a bispecific PD-1/CTLA-4 VHH therapeutic designed to provide the efficacy of combination checkpoint inhibition with a safer, subcutaneous dosing profile.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:VHH (Single-domain antibody), Bispecific antibodies, Antibody-drug conjugates (ADC)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Scientific Advisory Board includes experts from MD Anderson and UCLA
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Vikram Kansra - Founder & CEO
Alison Finger - Chief Operating Officer
Han Myint - Chief Medical Officer
Scientific Founders:Vikram Kansra
LINKS
Website:vicerobio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vicero Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.